{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T08:26:45Z","timestamp":1759480005903},"reference-count":31,"publisher":"The Journal of Rheumatology","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2020,4]]},"abstract":"Objective.<\/jats:title>To assess clinical benefit in patients with chronic refractory gout who did not meet the protocol-defined criteria of responders to pegloticase.<\/jats:p><\/jats:sec>Methods.<\/jats:title>This analysis used results from 2 randomized controlled trials (ClinicalTrials.gov<\/jats:ext-link>: NCT00325195<\/jats:ext-link>, NCT01356498<\/jats:ext-link>) to assess the clinical efficacy in responders and nonresponders to treatment (8 mg of pegloticase every 2 weeks). Serum urate was measured before each infusion and the following were recorded: assessment of gout flares, tophus reduction, patient\u2019s global assessment (PtGA), tender and swollen joints (TJC and SJC), pain using a 100-mm visual analog scale, and a variety of patient-reported outcomes [Medical Outcomes Study Short Form-36 questionnaire physical component summary score and arthritis-specific health index (ASHI) score].<\/jats:p><\/jats:sec>Results.<\/jats:title>The analysis included 36 persistent urate responders, 49 nonresponders, and 43 patients who received placebo. Results for both responders and nonresponders indicated significant reduction in tophi and improvements from baseline in PtGA, TJC, SJC, pain, and ASHI. No significant improvements were observed in the patients who received placebo.<\/jats:p><\/jats:sec>Conclusion.<\/jats:title>Chronic refractory gout patients not achieving protocol-defined persistent urate lowering still achieve significant clinical benefits with pegloticase treatment, suggesting that transient reduction in serum urate may result in sustained clinical benefit.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.190161","type":"journal-article","created":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T16:24:08Z","timestamp":1560615848000},"page":"605-612","source":"Crossref","is-referenced-by-count":3,"title":["Dissociation Between Clinical Benefit and Persistent Urate Lowering in Patients with Chronic Refractory Gout Treated with Pegloticase"],"prefix":"10.3899","volume":"47","author":[{"given":"Michael H.","family":"Pillinger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore R.","family":"Fields","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony E.","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter E.","family":"Lipsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2019,6,15]]},"reference":[{"key":"2021110311500899000_47.4.605.1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21772"},{"key":"2021110311500899000_47.4.605.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209707"},{"key":"2021110311500899000_47.4.605.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203325"},{"key":"2021110311500899000_47.4.605.4","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s11926-013-0400-9","article-title":"The crystallization of monosodium urate","volume":"16","author":"Martillo","year":"2014","journal-title":"Curr Rheumatol Rep"},{"key":"2021110311500899000_47.4.605.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.23007"},{"key":"2021110311500899000_47.4.605.6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1169"},{"key":"2021110311500899000_47.4.605.7","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.144022"},{"key":"2021110311500899000_47.4.605.8","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.111375"},{"key":"2021110311500899000_47.4.605.9","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1007\/s10067-018-4065-7","article-title":"Improvement in OMERACT domains and renal function with regular treatment for gout: a 12-month follow-up cohort study","volume":"37","author":"Vazquez-Mellado","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2021110311500899000_47.4.605.10","unstructured":"U.S. Food and Drug Administration . Table of surrogate endpoints that were the basis of drug approval or licensure. [Internet. Accessed October 2, 2019.] Available from: www.fda.gov\/drugs\/development-resources\/table-surrogate-endpoints-were-basis-drug-approval-or-licensure"},{"key":"2021110311500899000_47.4.605.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211873"},{"key":"2021110311500899000_47.4.605.12","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1093\/rheumatology\/kex350","article-title":"Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6-month phase 3 clinical trial and extension study","volume":"56","author":"Tausche","year":"2017","journal-title":"Rheumatology"},{"key":"2021110311500899000_47.4.605.13","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/art.40159","article-title":"Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: findings of a phase III clinical trial","volume":"69","author":"Dalbeth","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2021110311500899000_47.4.605.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.20405"},{"key":"2021110311500899000_47.4.605.15","doi-asserted-by":"publisher","DOI":"10.1002\/art.10511"},{"key":"2021110311500899000_47.4.605.16","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000075"},{"key":"2021110311500899000_47.4.605.17","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3283257b83"},{"key":"2021110311500899000_47.4.605.18","doi-asserted-by":"publisher","DOI":"10.1186\/ar4497"},{"key":"2021110311500899000_47.4.605.19","first-page":"1111","article-title":"First application of computer-assisted analysis of digital photographs for assessing tophus response: phase 3 studies of pegloticase in treatment failure gout","volume":"60","author":"Maroli","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2021110311500899000_47.4.605.20","first-page":"334","article-title":"Placebo-related effects: a meta-narrative review of conceptualization, mechanisms and their relevance in rheumatology","volume":"56","author":"Coste","year":"2017","journal-title":"Rheumatology"},{"key":"2021110311500899000_47.4.605.21","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1007\/s10067-017-3729-z","article-title":"Comparison of dual-energy CT, ultrasound and surface measurement for assessing tophus dissolution during rapid urate debulking","volume":"36","author":"Modjinou","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2021110311500899000_47.4.605.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.23993"},{"key":"2021110311500899000_47.4.605.23","doi-asserted-by":"publisher","DOI":"10.1186\/ar4318"},{"key":"2021110311500899000_47.4.605.24","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s13075-018-1782-x","article-title":"Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase","volume":"20","author":"Mandell","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2021110311500899000_47.4.605.25","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.071229"},{"key":"2021110311500899000_47.4.605.26","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq346"},{"key":"2021110311500899000_47.4.605.27","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-10-117"},{"key":"2021110311500899000_47.4.605.28","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem150"},{"key":"2021110311500899000_47.4.605.29","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket265"},{"key":"2021110311500899000_47.4.605.30","doi-asserted-by":"crossref","unstructured":"Lawrence Edwards N Singh JA Troum O Yeo AE Lipsky PE . Characterization of patients with chronic refractory gout who do and do not have clinically apparent tophi: response to pegloticase. Rheumatology 2019 Mar 6 (E-pub ahead of print).","DOI":"10.1093\/rheumatology\/kez017"},{"key":"2021110311500899000_47.4.605.31","doi-asserted-by":"publisher","DOI":"10.1002\/art.22232"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.190161","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T18:52:34Z","timestamp":1635965554000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.190161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,15]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4,1]]},"published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.3899\/jrheum.190161"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.190161","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,15]]}}}